Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
Cited by 0
Related Papers
Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer
|BMC Cancer|2018|82
CD47 Enhances Cell Viability and Migration Ability but Inhibits Apoptosis in Endometrial Carcinoma Cells via the PI3K/Akt/mTOR Signaling Pathway
|Frontiers in Oncology|2020|54
PHF5A promotes colorectal cancer progression by alternative splicing of TEAD2
|Molecular Therapy — Nucleic Acids|2021|42
<scp>METTL3</scp>‐induced <scp>FGD5‐AS1</scp> contributes to the tumorigenesis and <scp>PD‐1</scp>/<scp>PD‐L1</scp> checkpoint to enhance the resistance to paclitaxel of endometrial carcinoma
|Journal of Cellular and Molecular Medicine|2023|10
Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
|Cancer Cell International|2021|9